The investigation evaluating the practices of Orzaks İlaç ve Kimya Sanayi Ticaret AŞ (ORZAKS) including restricting pharmacies’ online sales, imposing purchasing obligations on pharmacies, requiring certain product groups to be stocked together, and excluding competitors through various discount practices under Articles 4 and 6 of the Act No. 4054 on the Protection of Competition, has been concluded by the Competition Board (the Board) within the framework of commitment and settlement procedures.

As a result of the settlement procedure, the Board took the decision dated 16.04.2026 and numbered 26-14/401-156 to impose an administrative fine of 35,681,375.91 TL on ORZAKS for violating Article 4 of the Act No. 4054 by restricting pharmacies’ online sales.

Regarding the competition concerns arising from the allegations that ORZAKS excluded its competitors from the pharmacy channel through purchasing obligations imposed on pharmacies, requirements to stock certain product groups together, and various discount practices, the commitments submitted by ORZAKS were accepted by the Board with its decision dated 16.04.2026 and numbered 26-14/402-157, and were made binding for ORZAKS.

The commitments submitted by ORZAKS, which will be reported annually for a period of five years, are as follows:

• No shelf or meal voucher (ticket) support will be provided for vitamin D3 and D3K2 products, and these products will be excluded from vacation campaigns that may be organized for pharmacists. 
• Pharmacies across the country will be categorized as “Pharmacies at Specific Locations” and “Other Pharmacies,” and in cases where purchasing support is provided to pharmacies, such support will be determined based on objective criteria according to this distinction. 
• No discounts will be applied for products other than vitamin D3 and D3K2 either, with the exception of surplus products. 
• Apart from the surplus products practice, uniform periodic campaigns such as promotional materials for final consumers, extra products, or discounted products may be organized during certain periods. 
• The statement “Distributors are free to choose the products they prefer” will be clearly written at the end of the Orzaks product list in a readable font size. 
• Contracts will include a provision stating that pharmacies are free to use the shelves as they wish, allocating space to and ensuring the visibility of competing products.